格拉司琼透皮贴剂预防化疗引起的恶心和呕吐的随机、阳性药平行对照双盲双模拟、多中心的临床试验
[Translation] A randomized, active-controlled, double-blind, double-dummy, multicenter clinical trial of granisetron transdermal patch for preventing chemotherapy-induced nausea and vomiting
评价格拉司琼透皮贴剂用于预防中重度致吐性抗肿瘤化疗引起的恶心和呕吐患者的有效性和安全性,为其在中国进行药品注册提供科学可靠的临床数据。
[Translation] To evaluate the efficacy and safety of granisetron transdermal patch in preventing nausea and vomiting caused by moderate to severe emetogenic anti-cancer chemotherapy, and to provide scientific and reliable clinical data for its drug registration in China.
/ CompletedNot Applicable 一项开放、随机、单中心、双交叉试验,比较格拉司琼透皮贴和格拉司琼片在中国健康受试者中的药代动力学特征
[Translation] An open-label, randomized, single-center, double-crossover trial comparing the pharmacokinetics of granisetron transdermal patch and granisetron tablets in healthy Chinese subjects
主要目的:比较在上臂外侧单次贴敷52cm2格拉司琼透皮贴剂连续6天与连续5天每日两次口服1mg格拉司琼片在中国健康人体内的药代动力学特征。
次要目的:评价格拉司琼透皮贴剂的局部耐受性和安全性。
[Translation] Primary objective: To compare the pharmacokinetic characteristics of a single 52 cm2 granisetron transdermal patch applied on the outer side of the upper arm for 6 consecutive days with oral administration of 1 mg granisetron tablets twice daily for 5 consecutive days in healthy Chinese subjects.
Secondary objective: To evaluate the local tolerability and safety of the granisetron transdermal patch.
评价SOM230长效制剂与奥曲肽长效制剂治疗活动期肢端肥大症安全性及疗效的多中心、随机、双盲临床研究
[Translation] A multicenter, randomized, double-blind clinical study to evaluate the safety and efficacy of SOM230 long-acting preparation and octreotide long-acting preparation in the treatment of active acromegaly
评价SOM230长效制剂与奥曲肽长效制剂治疗活动期肢端肥大症的安全性及疗效
[Translation] To evaluate the safety and efficacy of SOM230 long-acting preparation and octreotide long-acting preparation in the treatment of active acromegaly
100 Clinical Results associated with Excel Pharma Studies, Inc.
0 Patents (Medical) associated with Excel Pharma Studies, Inc.
100 Deals associated with Excel Pharma Studies, Inc.
100 Translational Medicine associated with Excel Pharma Studies, Inc.